What is the average duration of resistance to ensidipine?

Enasidenib (Enasidenib) is a targeted therapy for acute myeloid leukemia (AML) carrying IDH2 mutations. The resistance time varies depending on individual patient differences, disease characteristics, and treatment options. Although ensidipine has shown some efficacy in treating AML, some patients may develop drug resistance after a period of treatment.

Studies have shown that the resistance time to ensidipine varies among individual patients, and the average resistance time may range from a few months to a year. Some patients may develop resistance within a few months of treatment, while others may develop resistance after a longer period of treatment.

Ensidipine is usually used as monotherapy but is sometimes used in combination with other drugs. Combination therapy may prolong the patient's drug resistance time and slow down the development of ensidipine resistance in AML cells.

Although resistance to ensidipine treatmentAML is a challenge, researchers are working hard to find solutions, including the development of new targeted drugs, combination treatment regimens, and personalized treatment strategies to prolong patients' resistance time and improve treatment effects.

For patients who develop drug resistance, doctors may consider adjusting the treatment plan, such as replacing other treatment drugs or using other drugs in combination to maintain the therapeutic effect. In addition, participating in clinical trials is also a possible option to find new treatment strategies and drugs.

In summary, the resistance time to ensidipine treatmentAML varies depending on individual patient differences and treatment regimens, and the average resistance time may range from a few months to a year. Through individualized treatment, combined treatment and close monitoring, patients' resistance time can be extended, treatment effects can be improved, and patients can be provided with better clinical prognosis.